Report Description Table of Contents What Is the BK Virus Infection Market Size and Why Is Kidney Transplantation Central to Its Growth? – (Updated On: 01-Sep-2026) The Global BK Virus Infection Market was valued at USD 0.21 billion in 2025 and is projected to reach USD 0.68 billion by 2032, expanding at a CAGR of 18.3% during 2026–2032, according to Strategic Market Research. BK polyomavirus is highly prevalent, with around 80–90% of adults globally and in the USA exposed, usually during childhood. The virus generally remains latent in the kidneys and urinary tract but can reactivate in immunocompromised patients. Kidney transplant recipients face the greatest risk, with BK viruria reported in 30–60%, viremia in 10–30%, and BK virus nephropathy in 1–10%. In a multicenter U.S. kidney transplant study, 17% of recipients developed BK viremia and 2% developed biopsy-confirmed BK virus nephropathy. Among stem cell transplant recipients, BK-associated hemorrhagic cystitis affects about 10–25% of patients. These risks support routine quantitative molecular surveillance using FDA-cleared platforms such as Roche cobas BKV and Abbott Alinity m BKV. The therapeutic pipeline is also progressing, with potravitug, MAU868, AIC468, and SyB V-1901 under development. Ipsen’s acquisition of Memo Therapeutics and Asahi Kasei’s acquisition of AiCuris further demonstrate growing commercial interest. Overall, rising transplant-related disease burden, improved diagnostics, and emerging targeted therapies are expected to drive strong market expansion while improving long-term graft protection and patient outcomes. BK Virus Infection Market Key Report Takeaways By Infection Type Subsegment 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Summary BK Viruria 16.0% USD 33.60 million 16.9% Represents an earlier reactivation state that can precede clinically consequential plasma DNAemia. BK Viremia 30.0% USD 63.00 million 18.4% Quantitative plasma viral load directly influences monitoring intensity and immunosuppression decisions. BK Virus Nephropathy 34.0% USD 71.40 million 19.2% Leads infection types because confirmed graft injury creates the highest-intensity diagnostic and management pathway. Hemorrhagic Cystitis 20.0% USD 42.00 million 17.7% Commercial activity is concentrated in hematopoietic stem-cell transplantation and severely immunocompromised care. By Diagnosis Subsegment 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Summary PCR/NAAT Testing 58.0% USD 121.80 million 19.3% Dominates because serial quantitative BKPyV DNAemia measurement is embedded in post-kidney-transplant surveillance. Serology 12.0% USD 25.20 million 15.1% Mainly supports exposure and immune-status assessment rather than active-disease management. Urine Cytology 15.0% USD 31.50 million 16.1% Serves as an adjunctive or lower-resource screening approach. Biopsy-Based Diagnosis 15.0% USD 31.50 million 18.4% Particularly important when graft injury must be distinguished from rejection or another cause of dysfunction. By Treatment Approach Subsegment 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Summary Reduction of Immunosuppression 42.0% USD 88.20 million 15.9% Remains the principal management strategy for sustained BKPyV DNAemia; the segment reflects BK-attributable management activity rather than sales of a BK-specific drug. Antiviral & Adjunctive Therapies 27.0% USD 56.70 million 18.4% Available options are largely off-label and lack a consistently effective BK-specific standard. Intravenous Immunoglobulin 16.0% USD 33.60 million 16.9% Used selectively in complex transplant pathways despite limited evidence for routine BK treatment. Emerging Therapies 15.0% USD 31.50 million 24.4% Leads treatment growth; the allocation reflects development-stage commercial activity and future addressable value, not approved BK-drug sales in 2025. By Transplant Type Subsegment 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Summary Kidney Transplant 64.0% USD 134.40 million 18.1% Dominates because BKPyV can directly damage the renal allograft and is monitored systematically after transplantation. Hematopoietic Stem Cell Transplant 25.0% USD 52.50 million 19.4% BK-associated hemorrhagic cystitis forms the principal clinical pathway. Other Solid Organ Transplants 11.0% USD 23.10 million 17.1% Testing is more selective and less protocolized than in kidney transplantation. By End User Subsegment 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Summary Hospitals & Transplant Centers 55.0% USD 115.50 million 17.9% Lead because these institutions control surveillance, biopsy, immunosuppression modification and graft-management decisions. Diagnostic Laboratories 23.0% USD 48.30 million 18.9% Capture recurring molecular viral-load testing and centralized transplant-virology workflows. Specialty Clinics 12.0% USD 25.20 million 16.4% Support outpatient nephrology follow-up and longitudinal immunosuppression management. Academic & Research Institutes 10.0% USD 21.00 million 20.4% Lead end-user growth as BK-specific clinical trials, biomarker work and therapeutic development expand. By Geography Region 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Summary North America 42.0% USD 88.20 million 17.6% Leads through transplant scale, FDA-cleared quantitative assays and active therapeutic development. Europe 28.0% USD 58.80 million 18.1% Supported by mature transplant networks, specialist molecular laboratories and an active orphan-drug development environment. Asia Pacific 21.0% USD 44.10 million 20.6% Leads regional growth as transplant capacity and molecular-testing infrastructure broaden. Latin America 5.5% USD 11.55 million 16.1% Commercial activity is concentrated around major transplant centers and public laboratory networks. Middle East & Africa 3.5% USD 7.35 million 17.1% The addressable market is concentrated in tertiary transplant institutions with molecular-virology capability. Defining the BK Virus Infection Market: Diagnostics, Transplant Management, and Emerging Therapeutics SMR treats the BK Virus Infection Market as a hybrid transplant-infectious-disease market that includes BK-attributable diagnostic products and laboratory testing, disease-management expenditure, adjunctive treatment utilization, and identifiable clinical-development activity. It should not be interpreted as a pure pharmaceutical-sales market. In particular, “reduction of immunosuppression” represents the clinical monitoring and management resources attributable to dose modification rather than revenue created by lowering an immunosuppressive drug dose; “emerging therapies” represents development-stage commercial activity and future addressable value, not 2025 sales of an approved BK-specific medicine. The infection-type categories are also market-allocation states rather than mutually exclusive epidemiologic populations. BK viruria can progress to plasma DNAemia and then to BKPyV-associated nephropathy in the same patient, so the 16.0%, 30.0% and 34.0% shares should not be read as independent prevalence estimates. The supplied segmentation is mathematically coherent: every 2025 segmentation view totals USD 210 million, and applying the supplied subsegment CAGRs produces approximately USD 678–682 million in 2032, consistent with the USD 680 million global forecast. BK Virus Infection Market Value Shifts from Early Viral Reactivation to Graft-Damaging Nephropathy BK Viruria accounted for 16.0% of the market, representing USD 33.60 million in 2025, and is projected to expand at a CAGR of 16.9% during 2026–2032. Viruria is an early marker of BKPyV reactivation and can identify patients who warrant closer follow-up, but urine positivity alone is less tightly linked to treatment decisions than plasma DNAemia or biopsy-confirmed nephropathy. The 2024 international consensus allows urine cytology at comparable screening time points in resource-limited settings, with plasma DNAemia testing when decoy cells are present. [1] BK Viremia held a 30.0% share, equivalent to USD 63.00 million in 2025, and is projected to expand at an 18.4% CAGR. Plasma DNAemia has a stronger commercial link to treatment decisions because sustained concentrations above 1,000 copies/mL or values above 10,000 copies/mL can trigger predefined reductions in immunosuppression. FDA-cleared assays from Abbott and Roche are positioned directly in this serial quantitative workflow, making viremia the point where diagnostic testing most clearly converts into management activity. [1,3,4] BK Virus Nephropathy represented the largest infection-type segment at 34.0%, generating USD 71.40 million in 2025, and is projected to grow at a CAGR of 19.2%. This category captures the most resource-intensive part of the pathway because viral replication is accompanied by renal-allograft injury, often requiring repeated PCR, pathology assessment and tighter graft surveillance. An Australia–New Zealand registry analysis of 14,697 kidney-transplant recipients identified BKPyV-associated nephropathy in 460 patients (3%); affected recipients had a 2.49-fold higher adjusted risk of death-censored graft loss. That graft-protection problem is the central commercial rationale for targeted therapeutic programs such as potravitug. [9] Hemorrhagic Cystitis accounted for 20.0% of the market, representing USD 42.00 million in 2025, and is projected to grow at a CAGR of 17.7%. Its economics differ from kidney-transplant BKPyVAN because the clinical pathway is concentrated in allogeneic hematopoietic stem-cell transplantation and is less standardized. A 2025 EBMT survey found BK testing available in 93% of responding centers but routine post-HCT surveillance in only 39%; 85% of centers reported intravenous or intrabladder cidofovir use when BKPyV infection was present, illustrating substantial practice variation and the absence of a validated targeted standard. [10] Quantitative PCR Anchors Recurring Revenue Across the BK Virus Infection Diagnostic Pathway PCR/NAAT Testing dominated diagnosis with a 58.0% share, representing USD 121.80 million in 2025, and is projected to expand at a CAGR of 19.3%. The segment leads because the care pathway requires serial quantitation, not simply proof of previous infection. International consensus recommends monthly plasma BKPyV DNAemia screening through month nine after kidney transplantation and every three months until two years post-transplant. An SMR analyst calculation based on that schedule implies approximately 14 routine plasma screening points during the first 24 months for an uncomplicated adult kidney recipient, before additional confirmatory or follow-up tests are considered. Roche cobas BKV and Abbott Alinity m BKV therefore compete inside a recurring reagent and laboratory-workflow market rather than a one-time diagnostic event. [1,3,4] Serology accounted for 12.0% of the diagnosis segment, representing USD 25.20 million in 2025, and is projected to grow at a CAGR of 15.1%. BKPyV exposure is widespread, so antibody positivity has less value for determining whether an immunosuppressed patient currently has clinically actionable viral replication. The subsegment consequently remains more relevant to immune-status characterization, epidemiologic research and selected donor-recipient investigations than to routine post-transplant treatment decisions. Older mechanistic and clinical literature supplied for this report also supports the distinction between latent exposure and active replication requiring PCR-based assessment. [11,12] Urine Cytology held 15.0% of the diagnosis market at USD 31.50 million in 2025 and is projected to expand at a CAGR of 16.1%. Identification of decoy cells can provide a lower-cost signal of polyomavirus replication and remains useful where plasma molecular testing is difficult to deploy. Its commercial ceiling is lower than quantitative PCR because a positive urine finding generally requires further assessment before clinicians modify immunosuppression or classify probable nephropathy. [1] Biopsy-Based Diagnosis represented 15.0% of the market, equivalent to USD 31.50 million in 2025, and is projected to expand at an 18.4% CAGR. Biopsy is most important when clinicians need to establish BKPyV-associated nephropathy or distinguish viral injury from acute rejection, two conditions that can lead to opposite immunosuppression decisions. The consensus guideline also limits unnecessary procedure volume by noting that adult patients without graft dysfunction do not routinely require allograft biopsy unless immunological risk is high, which keeps biopsy concentrated in higher-complexity cases rather than first-line screening. [1] The BK Virus Infection Treatment Market Remains Management-Led as Targeted Therapies Advance Reduction of Immunosuppression represented 42.0% of the treatment-approach allocation, equivalent to USD 88.20 million in 2025, and is projected to grow at a CAGR of 15.9%. This is a management-expenditure category rather than BK-specific drug sales. It remains the dominant pathway because reducing antiproliferative agents, calcineurin inhibitors or both can restore host antiviral control, but the same intervention can increase rejection risk. Both the 2015 review supplied for this report and the 2024 international consensus identify immunosuppression reduction as the core evidence-based strategy. [1,13] Antiviral & Adjunctive Therapies accounted for 27.0% of the treatment-approach market, representing USD 56.70 million in 2025, and are projected to expand at an 18.4% CAGR. This SMR category excludes IVIG to avoid overlap. Cidofovir, leflunomide and fluoroquinolones have been used or investigated in practice, but the supplied 2023 review describes nephrotoxicity as a limitation for cidofovir and no established benefit from fluoroquinolones; the 2024 consensus states that current studies do not support routine use of leflunomide, cidofovir, quinolones or IVIG. Commercially, the segment remains fragmented because no incumbent product has established a durable BK-specific franchise. [1,14] Intravenous Immunoglobulin accounted for 16.0% of the treatment-approach market, representing USD 33.60 million in 2025, and is projected to expand at a CAGR of 16.9%. IVIG is used selectively as an adjunct in complex transplant cases and can add neutralizing antibody activity, but current consensus does not support routine IVIG as an established BKPyV treatment. Its revenue therefore reflects selective use within broader transplant care rather than a disease-specific standard. [1,14] Emerging Therapies represented 15.0% of the treatment-approach allocation at USD 31.50 million in 2025 and carry the fastest CAGR at 24.4%. This allocation reflects research, development and future addressable treatment value rather than 2025 marketed drug sales. Potravitug has completed Phase II development, while AIC468 has completed Phase I and has a registered seamless Phase 2/3 protocol. These programs matter because a successful targeted agent could convert part of the current management expenditure into a distinct branded pharmaceutical revenue stream. [5–8] Kidney Transplantation Forms the Core Patient and Revenue Pathway for BK Virus Infection Kidney Transplant dominated the transplant-type segment with a 64.0% share, representing USD 134.40 million in 2025, and is projected to expand at a CAGR of 18.1%. The commercial pathway starts at transplantation and extends through protocolized PCR surveillance, repeat testing after DNAemia, immunosuppression adjustment and graft assessment. HRSA reported 27,759 kidney transplants in the U.S. during 2024, while global registry data released on 31 August 2026 recorded 183,896 organ transplants across 96 countries in 2025, up 4% year over year. Every additional functioning kidney graft adds to the population requiring ongoing post-transplant virological management. [15,16] Hematopoietic Stem Cell Transplant accounted for 25.0% of the market, equivalent to USD 52.50 million in 2025, and is forecast to expand at a CAGR of 19.4%. The principal BK-associated complication is hemorrhagic cystitis rather than renal-allograft nephropathy, so the revenue pathway is more episodic and treatment practices are less standardized. The EBMT survey’s 93% access to BK testing but 39% routine post-HCT surveillance supports the view that this setting is clinically important but less predictable as a recurring testing market than kidney transplantation. [10] Other Solid Organ Transplants represented 11.0% of the market at USD 23.10 million in 2025 and are projected to grow at a CAGR of 17.1%. Heart, lung, liver and multi-organ recipients can experience BK reactivation under substantial immunosuppression, but routine BK screening and treatment triggers are not as consistently embedded as in kidney-transplant protocols. This keeps the segment more selective and limits the size of a standardized testing funnel. Transplant Centers and Molecular Laboratories Control BK Virus Testing and Treatment Adoption Hospitals & Transplant Centers accounted for 55.0% of the end-user market, representing USD 115.50 million in 2025, and are projected to grow at a CAGR of 17.9%. These institutions control the high-value decisions that determine BK-related utilization: surveillance schedules, viral-load interpretation, biopsy, immunosuppression changes, rejection management and eventual adoption of a targeted therapy. The concentration of kidney transplantation in specialist centers also makes this a commercially focused call point for both diagnostic and pharmaceutical companies. Diagnostic Laboratories held 23.0% of the end-user market at USD 48.30 million in 2025 and are projected to expand at an 18.9% CAGR. Their economics are supported by repeated quantitative testing, automated platform utilization and reagent pull-through. Medicare states that medically necessary diagnostic laboratory tests are generally covered under Part B and that patients pay nothing for Medicare-approved laboratory tests associated with kidney transplantation. Margin pressure remains relevant: CMS reports no CLFS phase-in reduction in 2026, but affected test payments may decline by up to 15% per year during 2027–2029, strengthening the value of high-throughput workflows and broader transplant-pathogen menus. [17–19] Specialty Clinics represented 12.0% of the end-user market at USD 25.20 million in 2025 and are projected to grow at a CAGR of 16.4%. Their role is concentrated in longitudinal nephrology and transplant follow-up after the most intensive early post-transplant period, including review of viral-load trends, kidney function and maintenance immunosuppression. They generate recurring management activity but generally rely on transplant centers and clinical laboratories for higher-complexity testing and procedures. Academic & Research Institutes accounted for 10.0% of the market, representing USD 21.00 million in 2025, and are forecast to grow at the fastest end-user CAGR of 20.4%. Within the SMR market definition, this category captures clinical-trial services, research testing, assay and reagent utilization, biomarker work and therapeutic-development activity. Its trajectory is supported by controlled BK-specific programs such as SAFE KIDNEY II and the advancing AIC468 clinical program rather than by routine outpatient care alone. [5–8] North America Leads BK Virus Infection Commercialization as Asia Pacific Accelerates Transplant Capacity North America accounted for 42.0% of the market, representing USD 88.20 million in 2025, and is projected to expand at a CAGR of 17.6%. The region combines transplant scale, structured surveillance and direct access to FDA-cleared quantitative assays. HRSA reported 48,149 total U.S. organ transplants in 2024, including 27,759 kidney transplants, while Canada performed 1,921 kidney transplants in 2025. Abbott and Roche both compete with FDA-cleared BK viral-load assays, and the U.S. has been central to potravitug clinical development, making North America the most developed intersection of diagnostics and emerging therapeutics. [3,4,15,20] Europe held 28.0% of the market, equivalent to USD 58.80 million in 2025, and is projected to grow at a CAGR of 18.1%. Spain performed 3,998 kidney transplants in 2025, while the UK reported 3,058 adult kidney-only transplants in 2024/25; the European Union recorded 32,816 organ transplants in 2025. The region also supports multiple BK molecular-diagnostics portfolios from QIAGEN, ELITechGroup and altona Diagnostics. Potravitug received EU orphan designation in December 2025, but the designation is not a marketing authorization, so pharmaceutical revenue remains prospective. [16,21–25] Asia Pacific represented 21.0% of the market, valued at USD 44.10 million in 2025, and has the fastest regional CAGR at 20.6%. Australia performed 1,064 kidney-transplant operations in 2024 and had 14,100 people with kidney failure living with a functioning transplant. The prevalent graft population is commercially important because surveillance continues after the procedure year. Regional commercialization is likely to remain concentrated initially in tertiary transplant centers and centralized molecular laboratories, while Asahi Kasei’s ownership of AiCuris adds a major Asia-headquartered pharmaceutical participant to the BK pipeline. [7,26] Latin America accounted for 5.5% of the market, representing USD 11.55 million in 2025, and is projected to expand at a CAGR of 16.1%. Commercial activity is concentrated around large public and private transplant networks rather than community-level BK exposure. Brazil’s National Transplant System reports that the Ministry of Health fully finances transplant-process activities and roughly 95% of transplantation in the country, making public laboratory capacity, centralized molecular access and reimbursement execution central to the regional commercial pathway. [27] Middle East & Africa represented 3.5% of the market, valued at USD 7.35 million in 2025, and is projected to grow at a CAGR of 17.1%. The addressable market is concentrated in specialist tertiary institutions with kidney-transplant and molecular-virology capability. Saudi Arabia illustrates this center-led pattern: King Faisal Specialist Hospital and Research Centre reported 130 paired kidney-donation transplants in 2025 and more than 5,000 kidney transplants cumulatively, supporting an advanced post-transplant monitoring environment within a comparatively concentrated institutional network. [28] BK Virus Infection Competition Divides Between Established PCR Platforms and Emerging Drug Developers Competitive positioning is currently asymmetric. Diagnostics companies compete on quantitative performance, automation, installed instruments, turnaround time and breadth of transplant-pathogen menus, while pharmaceutical developers compete on viral suppression, graft preservation, safety under immunosuppression and ability to reach pivotal endpoints. The absence of an approved BK-specific drug means the diagnostic installed base is already commercial, whereas the therapeutic landscape still carries substantial clinical-development risk. Abbott Laboratories Abbott competes through Alinity m BKV, an FDA-cleared quantitative nucleic-acid assay for the Alinity m system. FDA issued a 510(k) substantial-equivalence decision on 24 March 2025. Its market relevance is the ability to add BK viral-load testing to a high-throughput molecular platform already serving large clinical laboratories, supporting recurring reagent utilization without dedicated BK instrumentation. [3] Roche Diagnostics Roche’s cobas BKV received FDA 510(k) clearance in September 2020 and quantifies BK DNA in EDTA plasma on cobas 6800/8800 systems. FDA describes the assay as an aid in transplant-patient management, including serial measurements that can indicate potential treatment changes and assess viral response. Roche therefore competes through automated throughput and an established molecular installed base. [4] QIAGEN QIAGEN’s European BK portfolio includes artus quantitative PCR kits for Rotor-Gene Q and QIAsymphony RGQ workflows. Portfolio management is also changing: QIAGEN currently lists the 24-reaction artus BK Virus RG PCR Kit for discontinuation on 1 October 2026 or while stocks last, while other configurations remain listed. This is a useful indicator of platform and SKU rationalization within a mature molecular segment rather than an exit from BK testing altogether. [23] ELITechGroup ELITechGroup offers the quantitative BKV ELITe MGB Kit across ELITe InGenius, ELITe BeGenius and related workflows. The assay supports plasma and urine testing and is positioned as part of a broader immunocompromised-patient monitoring menu, which is commercially relevant for laboratories that prefer integrated transplant-virology testing rather than single-pathogen systems. [24] altona Diagnostics altona Diagnostics markets the AltoStar BKV PCR Kit 1.5 for quantitative BK DNA testing in plasma, whole blood and urine. The product is CE-IVD marked under the European IVDR framework and is explicitly not FDA cleared or approved. Its broad specimen compatibility and open instrument options support laboratories that require workflow flexibility across different transplant settings. [25] Ipsen / Memo Therapeutics Ipsen entered the BK-virus therapeutic field by completing its acquisition of Memo Therapeutics on 22 July 2026. The principal asset is potravitug, a VP1-directed monoclonal antibody that has completed Phase II development. Ipsen’s strategic significance comes from moving a specialist biotech program into a larger rare-disease development and commercialization organization, although the Phase II primary-endpoint result keeps pivotal execution risk central to the asset’s valuation. [5,6] Asahi Kasei / AiCuris / Veloxis Pharmaceuticals Asahi Kasei acquired AiCuris in 2026 and added AIC468 to a portfolio that can leverage Veloxis’s transplant-focused presence. AIC468 is a splice-modulating antisense oligonucleotide intended to inhibit BK replication directly within infected cells. With Phase I completed and a Phase 2/3 protocol registered, the program is differentiated by mechanism and by its fit with an existing transplant-commercial infrastructure, but it remains investigational. [7,8,29] AlloVir — Development-Risk Precedent AlloVir should not be presented as an active BK-virus pipeline leader. Its posoleucel Phase III programs were discontinued after futility analyses, and the company subsequently stated that it did not intend to resume development. The relevance for competitive analysis is historical: the setback demonstrates the high evidentiary bar for translating multi-virus or cell-therapy concepts into approvable transplant-infection products. [30] Diagnostics Provide the Revenue Base While Targeted Therapies Shape the BK Virus Infection Market Outlook to 2032 The most dependable component of the USD 0.68 billion 2032 forecast is recurring molecular surveillance. Kidney-transplant guidelines already specify repeated plasma BKPyV testing, global transplantation continues to expand, and major diagnostics companies have regulated or CE-marked quantitative products. The fresh global transplant registry update for 2025 recorded 183,896 organ transplants across 96 countries, 4% more than the prior year, which supports expansion of the underlying post-transplant population even before a new drug succeeds. [1,16] The largest upside variable is successful targeted therapy. A clinically validated BK antiviral or neutralizing antibody could convert part of today’s diffuse management expenditure into an identifiable branded pharmaceutical market and make existing PCR infrastructure function as a treatment-identification system. Potravitug and AIC468 are the two most commercially important current programs, but neither should be capitalized as approved-product revenue before pivotal efficacy and regulatory milestones are achieved. [5–8] The principal downside risks are clinical-development failure, ambiguous endpoints, effective viral control through immunosuppression reduction in a portion of patients, and laboratory reimbursement pressure. SAFE KIDNEY II did not show statistically significant separation on its original week-20 primary endpoint, and AlloVir’s Phase III discontinuations show that late-stage execution risk is real. On the diagnostics side, CMS permits CLFS payment reductions of up to 15% per year for affected tests during 2027–2029, which could pressure laboratory economics even if test volumes continue to expand. [6,19,30] For a strategic buyer, investor or diagnostic supplier, the market should therefore be viewed as two linked opportunities rather than one homogeneous category: a currently monetized transplant-virology surveillance business and a still-developing BK-specific pharmaceutical opportunity. Kidney transplantation remains the core setting because it combines an identifiable at-risk population, protocolized viral-load surveillance, measurable treatment thresholds, high economic consequences of graft loss and a concentrated network of specialist centers capable of adopting both new assays and future therapies. SMR Methodology and Source Framework for the BK Virus Infection Market Strategic Market Research preserves the proprietary 2025 market size, 2032 forecast, market shares and subsegment CAGRs supplied for this report. No market size, forecast, CAGR or market-share estimate from another market-research publisher has been used. Clinical and commercial interpretation is based on regulator databases, government transplant statistics, payer information, peer-reviewed publications, professional consensus guidance, clinical-trial records, SEC filings and official company materials. Healthcare-market classification: hybrid transplant infectious-disease diagnostics and management market with an emerging therapeutics layer. Primary commercial units include quantitative viral-load tests, pathology and follow-up episodes, BK-attributable treatment/management activity, and clinical-development services. Principal care settings are kidney-transplant centers, molecular laboratories, hematopoietic transplant centers and specialist nephrology clinics. Primary decision makers are transplant physicians, nephrologists, infectious-disease specialists, molecular-laboratory leadership and healthcare payers. BK Virus Infection Market Report Coverage Table Report Attribute Details Forecast Period 2026–2032 Market Size Value in 2025 USD 0.21 Billion Revenue Forecast in 2032 USD 0.68 Billion Overall Growth Rate 18.3% CAGR Base Year for Estimation 2025 Historical Data 2019–2024 Unit USD Billion Segmentation Infection Type, Diagnosis, Treatment Approach, Transplant Type, End User, and Geography By Infection Type BK Viruria, BK Viremia, BK Virus Nephropathy, and Hemorrhagic Cystitis By Diagnosis PCR/NAAT Testing, Serology, Urine Cytology, and Biopsy-Based Diagnosis By Treatment Approach Reduction of Immunosuppression, Antiviral & Adjunctive Therapies, Intravenous Immunoglobulin, and Emerging Therapies By Transplant Type Kidney Transplant, Hematopoietic Stem Cell Transplant, and Other Solid Organ Transplants By End User Hospitals & Transplant Centers, Diagnostic Laboratories, Specialty Clinics, and Academic & Research Institutes By Region North America, Europe, Asia Pacific, Latin America, and Middle East & Africa Country Scope United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Saudi Arabia, United Arab Emirates, and South Africa Market Drivers Expansion of the kidney-transplant population, protocolized BKPyV surveillance, recurring quantitative PCR testing, molecular-laboratory capacity, graft-protection requirements, and development of targeted monoclonal-antibody and antisense therapies Customization Option Available upon request. Frequently Asked Question About This Report Q1. What are the main factors driving market growth? A1. Growth is being driven by rising kidney-transplant volumes, protocolized post-transplant viral-load surveillance, and the high clinical cost of graft injury. Repeated PCR testing also creates recurring diagnostic demand long after the transplant procedure itself. Q2. What are the latest innovations transforming the industry? A2. Innovation is shifting from surveillance alone toward BK-specific therapeutic development. Potravitug introduces a monoclonal-antibody approach, while AIC468 uses antisense technology to interfere with viral replication inside infected cells. Q3. Why are companies investing in advanced solutions in the market? A3. There is currently no established BK-specific pharmaceutical standard, leaving a clear treatment gap beyond immunosuppression reduction and off-label adjunctive therapy. A successful targeted drug could create a new branded revenue pool while using existing PCR infrastructure to identify treatment-eligible patients. Q4. Which regions are expected to witness the fastest growth in the industry? A4. Asia Pacific is expected to grow the fastest as kidney-transplant capacity and molecular-testing infrastructure expand. Growth is likely to remain concentrated initially in tertiary transplant centers and centralized virology laboratories capable of supporting repeated quantitative testing. Q5. What factors could limit future market growth? A5. Clinical-development failure remains the largest pharmaceutical risk because targeted therapies still need to demonstrate meaningful viral and graft outcomes. Laboratory reimbursement pressure, variable surveillance outside kidney transplantation, and effective management through immunosuppression reduction in some patients can also constrain revenue expansion. Sources: [1] Kotton CN et al. The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation. Transplantation. 2024. [2] Seifert ME et al. A multicenter prospective study to define the natural history of BK viral infections in kidney transplantation. Transplant Infectious Disease. 2024. [3] U.S. FDA 510(k) K241921 — Alinity m BKV; substantial-equivalence decision 24 March 2025. [4] U.S. FDA 510(k) K202215 — cobas BKV; substantial-equivalence decision 2 September 2020. [5] Ipsen. Acquisition of Memo Therapeutics focused on potravitug; pivotal Phase II/III development planned. 1 July 2026. [6] American Society of Nephrology Kidney Week 2025 abstract — SAFE KIDNEY II Phase II potravitug results. [7] Asahi Kasei investor materials — AiCuris acquisition and AIC468 Phase I completion / planned advancement. February 2026. [8] ClinicalTrials.gov NCT07503561 — randomized adaptive seamless Phase 2/3 study of AIC468/AIC263029 in kidney-transplant recipients with BKV infection. [9] Australia/New Zealand registry analysis: 14,697 kidney-transplant recipients; BKPyVAN incidence and graft outcomes. Kidney International Reports. 2023. [10] EBMT Infectious Diseases Working Party survey of BKPyV/hemorrhagic-cystitis practices after allogeneic HCT. Bone Marrow Transplantation. 2025. [11] DZIF — BK virus clinical background and latent infection context. [12] Moriyama T, Sorokin A. BK Virus: infection, propagation, quantitation, purification, labeling, and analysis of cell entry. 2009. [13] Sawinski D, Goral S. BK virus infection: an update on diagnosis and treatment. Nephrology Dialysis Transplantation. 2015. [14] Gorriceta JH et al. BK viral infection: a review of management and treatment. World Journal of Transplantation. 2023. [15] HRSA/OPTN — U.S. organ transplants exceeded 48,000 in 2024; preliminary procedure counts including kidney transplantation. [16] Organización Nacional de Trasplantes / Global Observatory — 2025 worldwide organ-transplant activity, released 31 August 2026. [17] Medicare — Diagnostic laboratory test coverage. [18] Medicare — Kidney transplant coverage and laboratory-test cost sharing. [19] CMS — Clinical Laboratory Fee Schedule; 2026 reporting and 2027–2029 payment-reduction phase-in. [20] Canadian Institute for Health Information — 2025 organ-transplant statistics. [21] NHS Blood and Transplant — Annual Report on Kidney Transplantation 2024/25. [22] European Medicines Agency — potravitug orphan designation EU/3/25/3176, 15 December 2025. [23] QIAGEN — artus BK Virus PCR Kits CE; current product portfolio and planned 24-reaction RG kit discontinuation. [24] ELITechGroup — BKV ELITe MGB Kit quantitative BK DNA assay and IVDR-compliant workflow. [25] altona Diagnostics — AltoStar BKV PCR Kit 1.5 product and regulatory status. [26] Australian Institute of Health and Welfare — Kidney transplantation, updated May 2026. [27] Brazil Ministry of Health — Sistema Nacional de Transplantes reports and financing framework. [28] King Faisal Specialist Hospital & Research Centre — 130 paired kidney-donation transplants in 2025. [29] Open Forum Infectious Diseases — Phase I AIC468 first-in-human clinical data and antisense mechanism. 2026. [30] AlloVir Form 10-K — discontinuation of posoleucel Phase III programs following futility analyses. [31] Kidney Research UK — BK virus overview in kidney transplantation. [32] Organización Nacional de Trasplantes — Spain 2025 transplant activity, including 3,998 kidney transplants. Table of Contents - Global BK Virus Infection Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Infection Type, Diagnosis, Treatment Approach, Transplant Type, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Infection Type, Diagnosis, Treatment Approach, Transplant Type, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User Investment Opportunities in the BK Virus Infection Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Quantitative Molecular Surveillance, Kidney Transplant Monitoring, Graft Protection, Emerging Antiviral Therapies, Monoclonal Antibodies, and Antisense Therapeutics Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of BKPyV Surveillance, Kidney Transplant Management, and Emerging BK-Specific Therapeutics Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Clinical, and Reimbursement Factors Role of Quantitative PCR, Serial Viral-Load Monitoring, Biopsy, Immunosuppression Management, and Graft Surveillance in Market Expansion Clinical Development, Transplant-Center Adoption, Molecular-Laboratory Capacity, and Targeted Therapy Trends in BK Virus Infection Management Global BK Virus Infection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Infection Type: BK Viruria BK Viremia BK Virus Nephropathy Hemorrhagic Cystitis Market Analysis by Diagnosis: PCR/NAAT Testing Serology Urine Cytology Biopsy-Based Diagnosis Market Analysis by Treatment Approach: Reduction of Immunosuppression Antiviral & Adjunctive Therapies Intravenous Immunoglobulin Emerging Therapies Market Analysis by Transplant Type: Kidney Transplant Hematopoietic Stem Cell Transplant Other Solid Organ Transplants Market Analysis by End User: Hospitals & Transplant Centers Diagnostic Laboratories Specialty Clinics Academic & Research Institutes Market Analysis by Region: North America Europe Asia Pacific Latin America Middle East & Africa Regional Market Analysis North America BK Virus Infection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User Country-Level Breakdown: United States Canada Mexico Europe BK Virus Infection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific BK Virus Infection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America BK Virus Infection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa BK Virus Infection Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Abbott Laboratories Roche Diagnostics QIAGEN N.V. ELITechGroup altona Diagnostics GmbH Ipsen / Memo Therapeutics Asahi Kasei / AiCuris / Veloxis Pharmaceuticals AlloVir Seegene Inc. Thermo Fisher Scientific Inc. DiaSorin S.p.A. Eurofins Viracor Competitive Landscape and Strategic Insights Benchmarking Based on Quantitative PCR Capability, Regulatory Positioning, Molecular Testing Portfolio, Transplant-Center Reach, Clinical Development Strength, and Regional Presence Diagnostic Platform Qualification and Laboratory Workflow Capability Analysis Quantitative BK Viral-Load Testing Positioning Kidney Transplant Surveillance and BK Virus Nephropathy Management Competitiveness Emerging Antiviral, Monoclonal Antibody, and Antisense Therapy Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Infection Type, Diagnosis, Treatment Approach, Transplant Type, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Diagnostic and Therapeutic Vendors Regulatory, Clinical Development, and Reimbursement Risk Analysis Technology Adoption Trends Across PCR/NAAT Testing, Serology, Urine Cytology, Biopsy-Based Diagnosis, Immunosuppression Reduction, and Emerging Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Infection Type, Diagnosis, Treatment Approach, Transplant Type, and End User (2025 vs. 2032) Global BK Virus Infection Ecosystem and Value Chain Analysis